Walleye Capital’s Aclaris Therapeutics ACRS Stock Holding History

Walleye Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104K	Buy	+19,576	New	+$87.3K	﹤0.01%	3888
2025 Q2	–	Sell	-311,712	Closed	-$477K	–	4436
2025 Q1	$477K	Sell	311,712 -407,185	-57%	-$869K	﹤0.01%	2602
2024 Q4	$1.78M	Buy	+718,897	New	+$1.79M	﹤0.01%	1889
2023 Q4	–	Sell	-115,962	Closed	-$794K	–	4877
2023 Q3	$794K	Sell	115,962 -225,618	-66%	-$1.93M	﹤0.01%	2445
2023 Q2	$3.54M	Buy	341,580 +223,656	+190%	+$2.02M	0.01%	949
2023 Q1	$954K	Sell	117,924 -301,160	-72%	-$3.82M	0.01%	1195
2022 Q4	$6.6M	Buy	419,084 +149,136	+55%	+$2.4M	0.12%	211
2022 Q3	$4.25M	Buy	+269,948	New	+$4.25M	0.08%	267
2022 Q1	–	Sell	-10,341	Closed	-$150K	–	2254
2021 Q4	$150K	Buy	+10,341	New	+$157K	﹤0.01%	1563
2019 Q3	–	Sell	-55,000	Closed	-$120K	–	1851
2019 Q2	$120K	Buy	+55,000	New	+$300K	0.01%	1155

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Walleye Capital's ACRS Position: Q2 2026 in Review

Walleye Capital opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 19,576 shares worth $104K. The stake represents ﹤0.01% of the portfolio and ranks #3888 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ACRS as recently as Q1 2025.

Walleye Capital first reported a position in ACRS in Q2 2019 and has held it in 10 quarters since. The position peaked at $6.6M in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Walleye Capital held 19,576 shares of Aclaris Therapeutics worth $104K as of Q2 2026.
Aclaris Therapeutics was a new Walleye Capital position in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3888 holding.
Walleye Capital first reported a position in Aclaris Therapeutics in Q2 2019 and has held it in 10 quarters since.
Walleye Capital's Aclaris Therapeutics position peaked at $6.6M in Q4 2022.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.